Sugi Predict

Sugi Predict / Compounds / SCHEMBL542865

SCHEMBL542865

SCHEMBL542865

CC1(c2ccccc2)NC(=O)NC1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.59
▸ CYP2C9 P11712 2/20 0.59
▸ CACNA1F O60840 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ HTR2A P28223 1/20 0.59
▸ HRH1 P35367 1/20 0.59
▸ SCN1A P35498 1/20 0.59
▸ SCN4A P35499 1/20 0.59
▸ BLM P54132 1/20 0.59
▸ PMP22 Q01453 1/20 0.59
▸ CACNA1D Q01668 1/20 0.59
▸ KCNH2 Q12809 1/20 0.59
▸ CACNA1S Q13698 1/20 0.59
▸ CACNA1C Q13936 1/20 0.59
▸ SCN5A Q14524 1/20 0.59
▸ SCN2A Q99250 1/20 0.59
▸ SCN3A Q9NY46 1/20 0.59
▸ MMP2 P08253 1/20 0.59
▸ MMP9 P14780 1/20 0.59
▸ TNKS O95271 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4384456 1.00 ALDH1A1 (0.59) ALDH1A1CYP2C9CACNA1FMAPTHTR2A
SCHEMBL4384462 1.00 ALDH1A1 (0.59) ALDH1A1CYP2C9CACNA1FMAPTHTR2A
SCHEMBL6282916 0.98 ALDH1A1 (0.57) ALDH1A1CYP2C9CACNA1FMAPTHTR2A
SCHEMBL542225 0.89 TNKS (0.62) ALDH1A1CYP2C9CACNA1FMAPTHTR2A
SCHEMBL542561 0.82 LMNA (0.53) ALDH1A1CYP2C9CACNA1FMAPTHTR2A
SCHEMBL1092035 0.82 MEN1 (0.49) ALDH1A1CYP2C9CACNA1FMAPTHTR2A
SCHEMBL20134878 0.82 LMNA (0.53) ALDH1A1CYP2C9CACNA1FMAPTHTR2A
SCHEMBL4380000 0.82 MEN1 (0.49) ALDH1A1CYP2C9CACNA1FMAPTHTR2A
SCHEMBL4380003 0.82 MEN1 (0.49) ALDH1A1CYP2C9CACNA1FMAPTHTR2A
SCHEMBL10131744 0.80 LMNA (0.51) ALDH1A1CYP2C9CACNA1FMAPTHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 756 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115613085-A Brush silver-plating alloy plating solution for repairing silver-plated layer of open-type isolating switch and preparation method thereof 国网山东省电力公司电力科学研究院 2023-01-17 — — CN claimed
CN-114678122-A Cancer risk prediction method, system, device and medium 上海市第十人民医院 2022-06-28 — — CN claimed
CN-109020892-A A kind of S-5- methyl -5- phenyl hydantoin because preparation method 上海雅本化学有限公司 2018-12-18 — — CN claimed
CN-102797043-B Medicinal molecular fragment library and construction process thereof Tianli (Tianjin) Technology Co., Ltd. (CN) 2015-11-25 — — CN claimed
EP-2513017-B1 PROCESS FOR THE RESOLUTION OF ENANTIOMERS BY PREFERENTIAL EVAPORATIVE CRYSTALLIZATION UNIV ROUEN (FR) 2015-07-01 — — EP claimed
US-8907106-B2 Process for the resolution of enantiomers by preferential evaporative crystallization UNIVERSITE DE ROUEN (FR) 2014-12-09 — — US claimed
US-8822516-B2 Process for the preparation of iodides TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2014-09-02 — — US claimed
US-20130165658-A1 PROCESS FOR THE PREPARATION OF IODIDES TECHNION R&D FOUNDATION LTD. (IL) 2013-06-27 — — US claimed
EP-2513017-A1 PROCESS FOR THE RESOLUTION OF ENANTIOMERS BY PREFERENTIAL EVAPORATIVE CRYSTALLIZATION Universite de Rouen (FR) 2012-10-24 — — EP claimed
US-20120259127-A1 PROCESS FOR THE RESOLUTION OF ENANTIOMERS BY PREFERENTIAL EVAPORATIVE CRYSTALLIZATION UNIVERSITE DE ROUEN (FR) 2012-10-11 — — US claimed
WO-2011073300-A1 PROCESS FOR THE RESOLUTION OF ENANTIOMERS BY PREFERENTIAL EVAPORATIVE CRYSTALLIZATION UNIVERSITE DE ROUEN (FR) 2011-06-23 — — WO claimed
EP-0983334-A1 ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION Call, Krimhild (DE) 2000-03-08 — — EP claimed
US-6022409-A 5-METHYL-5-PHENYLHYDANTOIN, 5-METHYL-5-(4-METHYLPHENYL)HYDANTOIN, 5-ETHYL-5-PHENYLHYDANTOIN, 5-METHYL-5-(4-CHLOROPHENYL)HYDANTOIN, THREITOL, THE UNIVERSITY OF ROUEN (FR) 2000-02-08 — — US claimed
WO-1999001607-A2 ENZYMATIC OXIDATION SYSTEM WITH NOVEL ENZYMATIC-EFFECT ENHANCING COMPOUNDS CALL, KRIMHILD (DE) 1999-01-14 — — WO claimed
EP-0720595-B1 METHOD OF RESOLUTION OF TWO ENANTIOMERS BY CRYSTALLIZATION UNIV ROUEN (FR) 1998-12-23 — — EP claimed
WO-1998051772-A1 ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION CALL, KRIMHILD (DE) 1998-11-19 — — WO claimed
EP-0720595-A1 METHOD OF RESOLUTION OF TWO ENANTIOMERS BY CRYSTALLIZATION UNIVERSITE DE ROUEN (FR) 1996-07-10 — — EP claimed
WO-1995008522-A1 METHOD OF RESOLUTION OF TWO ENANTIOMERS BY CRYSTALLIZATION UNIVERSITE DE ROUEN (FR) 1995-03-30 — — WO claimed
US-4745189-A Method of preparing N-halogenated organic heterocyclic compounds ETHYL CORPORATION (US) 1988-05-17 — — US claimed
US-4668236-A IMIDAZOLIDINEDIONE L'OREAL (FR) 1987-05-26 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165658-A1 PROCESS FOR THE PREPARATION OF IODIDES NISCH, TPO, HDHD5 ALDH1A1 281/4885CYP2C9 44/4885CACNA1F 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.